Crossover trial comparing sera obtained from diabetic patients before and after pioglitazone administration on cholesterol efflux from macrophages

Crossover trial comparing sera obtained from diabetic patients before and after pioglitazone administration on cholesterol efflux from macrophages - Pioglitazone and cholesterol efflux

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004189

Enrollment

Registered

2010-09-15

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Oral administration of pioglitazone Oral administration of placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients who are treated with piogliitazone at least for 6 months and have good tolerance without relevant side effects

Exclusion criteria

Exclusion criteria: Poor-controlled diabetes (HbA1c>8.0 %)

Design outcomes

Primary

Measure	Time frame
Macrophage ABCA1/G1 expressions and cholesterol efflux cultured under sera obtained from diabetic patients	—

Countries

Japan

Contacts

Public ContactMakoto Ayaori

National Defense Medical College I Department of Internal Medicine

ayaori@ndmc.ac.jp04-2995-1597

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026